Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Recruiting
Phase 1
Interventional Study
Parkinson Disease
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24
Exclusion Criteria:
* 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders
2: Or have received deep brain stimulation and other brain surgery
3: Abnormal liver and kidney funct…
Contacts
No contact information available.